Antibody-associated polyneuropathy syndromes: Principles and treatment

Seminars in Neurology

Volumn 23, Issue 2, 2003, Pages 181-189

  Kornberg, Andrew J ^b,c   Pestronk, Alan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antibody; Cyclophosphamide; IgM; Intravenous immunoglobulin; Neuropathy; Rituximab

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; PREDNISONE; RITUXIMAB;

ANTIBODY TITER; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DEMYELINATION; ELECTROPHYSIOLOGY; HUMAN; IMMUNOTHERAPY; META ANALYSIS; MOTOR NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; DEMYELINATING DISEASES; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYELIN-ASSOCIATED GLYCOPROTEIN; NEUROMUSCULAR DISEASES; POLYNEUROPATHIES; SULFOGLYCOSPHINGOLIPIDS;

EID: 0042343607     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41131     Document Type: Review

References (73)

1. Van den Berg-Vos RM, Franssen H, Wokke JH, van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875-1886
2. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449
3. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262
4. Van Doorn PA, van der Meché FGA. IVIg treatment improves multifocal motor neuropathy: easy to start but difficult to stop. Neurology 2000;55:1246-1247
5. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998;51(suppl 5):S22-S24
6. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-1066
7. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077
8. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328
9. van den Berg LH, Lokhorst H, Wokke JHJ. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology 1997;48:1135
10. van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252
11. Pestronk A, Lopate G, Kornberg AJ, et al. Distal lower motor neuron syndrome with high titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 1994;44:2027-2031
12. Elliott JL, Pestronk A. Deterioration of multifocal motor neuropathy during apparently successfid treatment with human immune globulin. Neurology 1994;44:967-968
13. Vincent A. Antibodies to ion channels in paraneoplastic disorders. Brain Pathol 1999;9:285-291
14. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368
15. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000;23:453-477
16. Greenberg DA. Neuromuscular disease and calcium channels. Muscle Nerve 1999;22:1341-1349
17. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739-749
18. Kullmann DM. The neuronal channelopathies. Brain 2002;125:1177-1195
19. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999;9:275-284
20. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-1148
21. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 2000;23:1800-1818
22. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995;38:102-110
23. Jaeckle KA. Autoimmunity in paraneoplastic neurological syndromes: closer to the truth? Ann Neurol 1999;45:143-145
24. Steck AJ, Erne B, Gabriel JM, Schaeren-Wiemers N. Paraproteinaemic neuropathies. Brain Pathol 1999;9:361-368
25. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999;52:1701-1704
26. Pestronk A, Cornblath DR, Ilyas A, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78
27. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401
28. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995;45:1577-1580
29. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-717
30. Kornberg AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve 1994;17:100-104
31. Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 2002;25:828-836
32. Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45:168-173
33. Lopate G, Kornberg AJ, Yue J, Choksi R, Pestronk A. Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve. J Neurol Sci 2001;188:67-72
34. Pestronk A, Li F, Bieser K, et al. Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. Neurology 1994;44:1131-1137
35. Pestronk A, Li F, Griffin J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991;41:357-362
36. Kyle RA, Dyck PJ. Osteosclerotic myeloma (POEMS syndrome). In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo, JF, eds. Peripheral Neuropathy. Philadelphia: WB Saunders; 1993:1288-1293
37. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995;37(suppl 1):S32-S42
38. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998;338:1601-1607
39. Pestronk A. Paraneoplastic syndromes. Available at: http://www.neuro.wustl.edu/neuromuscular. Accessed July 2002
40. Dropcho EJ. Neurologic paraneoplastic syndromes. J Neurol Sci 1998;153:264-278
41. Scaravilli F, An SF, Groves M, Thom M. The neuropathology of paraneoplastic syndromes. Brain Pathol 1999;9:251-260
42. Giometto B, Scaravilli F. Paraneoplastic syndromes. Brain Pathol 1999;9:247-250
43. Giometto B, Taraloto B, Graus F. Autoimmunity in paraneoplastic neurological syndromes. Brain Pathol 1999;9:261-273
44. Grisold W, Drlicek M. Paraneoplastic neuropathy. Curr Opin Neurol 1999;12:617-625
45. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481-1494
46. Dalmau JO, Posner JB. Neurological paraneoplastic syndromes. Neuroscientist 1998;4:443-453
47. Erb S, Ferracin F, Fuhr P, et al. Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol 2000;247:767-772
48. Nobile-Orazio E. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ Jr, eds. Immunology and Infectious Diseases of the Peripheral Nerves. Cambridge, UK: Cambridge University Press; 1998;168-189
49. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;117:941-947
50. Van den Berg L, Hays AP, Nobile Orazio E, et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996;19:637-643
51. Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol 1999;95:174-184
52. Lopate G, Parks BJ, Goldstein JM, Yee WC, Friesenhahn GM, Pestronk A. Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins. J Neurol Neurosurg Psychiatry 1997;62:581-585
53. Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF. High-titre IgM anti-sulfatide antibodies in individuals with IgM paraproteinaemia and associated peripheral neuropathy. Immunol Cell Biol 2000;78:124-132
54. Carpo M, Meucci N, Allaria S, et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci 2000;176:144-150
55. Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF. High titre anti-sulphatide antibodies in HIV-infected individuals. Neuroreport 1999;10:2557-2562
56. Avila JL, Rojas M, Carrasco H. Elevated levels of antibodies against sulphatide are present in all chronic chagasic and non-chagasic dilatatory cardiomyopathy sera. Clin Exp Immunol 1993;92:460-465
57. Pestronk A, Choksi R, Bieser K, et al. Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle Nerve 1994;17:1293-1300
58. Pestronk A. Autoantibodies and Immune polyneuropathies. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, eds. Neuromuscular Disorders in Clinical Practice. Boston: Butterworth-Heinemann; 2002:64-73
59. Susuki K, Yuki N, Hirata K. Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody. J Neuroimmunol 2001;112:181-187
60. Ponsford S, Willison H, Veitch J, Morris R, Thomas PK. Long-term clinical and neurophysiological follow-up of patients with peripheral neuropathy associated with benign monoclonal gammopathy. Muscle Nerve 2000;23:164-174
61. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18
62. Nobile-Orazio E, Cappellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002;72:761-766
63. Parry GJ. AAEM case report #30: multifocal motor neuropathy. Muscle Nerve 1996;19:269-276
64. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-324
65. Pestronk A, Choksi R. Multifocal motor neuropathy: serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 1997;49:1289-1292
66. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-908
67. Van den Berg LH, Franssen H, Wokke JHJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121:421-428
68. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-153
69. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875-1886
70. Kaji R, Kusunoki S, Mizutani K, et al. Chronic motor axonal neuropathy associated with antibodies monospecific for N-acetylgalactosaminyl GD1a. Muscle Nerve 2000;23:702-706
71. Ortiz N, Rosa R, Gallardo E, et al. IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol 2001;119:114-123
72. Connolly AM, Pestronk A, Mehta S, et al. Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of b-tubulin: clinical association with slowly progressive demyelinating polyneuropathy. Neurology 1997;48:243-248
73. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Engl J Med 1992;327:1919-1923